System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Carlo Visco is an expert in Hematology at Azienda Ospedaliera Universitaria Integrata Verona (Italy). As of October 2026, ScienceLeadR ranks Carlo Visco in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Carlo Visco has authored 354 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 9 of them ongoing. SLR score: 1,434 (community average: 125). How the SLR is computed.

LeadR Profile

Carlo Visco Azienda Ospedaliera Universitaria Integrata Verona Italy
1 434 ScienceLeadR Reputation 1434

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

University of Verona

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 354

Citations

Citations: 10 319 1st author: 47 Last author: 46 Unique author: 2

Main journals

Blood 74
Hematol Oncol 30
Br J Haematol 21
Haematologica 17
Leuk Lymphoma 12

Best Journals

J Clin Oncol 2
Lancet 2
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Early Integration of CAR T-Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors.
PMID 42847438 — cells, hematology, lymphoma, lymphoma, mantle-cell, therapeutics, medical oncology, t-lymphocytes, car-t cell		Hematol Oncol20260
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
PMID 42498280 — cells, genes, lymphoma, biomarkers, lymph, lymphoma, mantle-cell, mutation		Blood Adv20260
Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies.
PMID 42779302 — cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes, prognosis, salvage therapy, car-t cell		Haematologica20260
Primary mediastinal B-cell lymphoma: a nationwide real-life retrospective study of first-line treatment approaches in Italy.
PMID 42779329 — cells, hematology, lymphoma, b-cell, lymphoma, retrospective studies, therapeutics, b-lymphocytes		Haematologica20260
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.
PMID 42669901 — hematology, lymphoma, therapeutics		Br J Haematol20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 2 11
N/A 5
Phase 3 3

By status:

Recruiting 10
Completed 6
Active not recruiting 2
Not yet recruiting 1

By type:

Interventional 14
Observational 5

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 17

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma
2022-501808-96-00 — cells, lymphoma, drug therapy, rituximab, lymphoma, mantle-cell, therapeutics, chemotherapy		Phase 2Recruiting2023
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients With Relapsed Refractory Mantle Cell Lymphoma
2024-515593-27-00 — cells, safety, lymphoma, lymphoma, mantle-cell		Phase 3Recruiting2025
Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to or relapsed after CAR T cell therapy
2025-523428-39-00 — cells, lymphoma, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell		Phase 2Recruiting2026
PirtobrUtinib as frontline Therapy for elderly unfit frail patient with MAntle cell lymphoma a phase II study of the Fondazione Italiana Linfomi (FIL)
2025-521666-10-01 — cells, lymphoma, aged, lymphoma, mantle-cell, therapeutics		Phase 2Recruiting2026
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T cell Therapy
NCT07453095 — cells, lymphoma, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS